About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2/3NCT01933321

Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)

Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.

Lead sponsor: Hospital Universitario Dr. Jose E. Gonzalez•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

There is no more extensive information

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years.
•Over 18 years old. Forced vital capacity ≥ 40%.
•One year of evolution.
•Adequate nutritional state

Exclusion Criteria

•Severe bulbar ALS involucre.
•Inadequate nutritional status.
•Spondylotic myelopathy, or abnormalities in imaging study.
•Having concomitant neurological or psychiatric disease.
•Systemic disease with poor-control.
•History of treatment with steroids or immunoglobulins in the last year.
•Participate in the past three months in a Clinical Trial.
•History of malignancy or cancer today.
•Intracranial hypertension.
•Clinical suggestive data of infection in the site of lumbar puncture.
•Tracheostomy.
•Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive or presence of antibodies against hepatitis B or C in the serological studies.

Related studies

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

NCT05204017 · Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, and more

RECRUITINGPhase 3

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003 · Amyotrophic Lateral Sclerosis

RECRUITINGPhase 1/2

Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

NCT07414212 · Amyotrophic Lateral Sclerosis

RECRUITINGPhase 1

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

NCT07401121 · ALS (Amyotrophic Lateral Sclerosis)

Intermuscular Coherence as a Biomarker for ALS

NCT05104710 · Amyotrophic Lateral Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 3, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment14

Start dateSep 2012

Last updatedApr 3, 2015

Condition

Amyotrophic Lateral Sclerosis

Locations shown

Servicio Hematología Hospital Universitario

Monterrey, Nuevo León

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2015Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions